Investigational drug · Phase 2
SHR-9839
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Advanced Esophageal Squamous Cell Carcinoma, Non-small Cell Lung Cancer (NSCLC).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
8
8 still active
All registered trials
9
Any phase or sponsor naming "SHR-9839"
First trial start
2024
Jul 2, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR-9839", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
- Advanced Esophageal Squamous Cell Carcinoma
- Non-small Cell Lung Cancer (NSCLC)
- Advanced KRAS G12D Mutant Solid Tumors
- Solid Tumor
- Advanced Malignant Tumour
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Stomach and esophageal cancer · Head and neck cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR-9839" as an intervention, largest first.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT06703177 · 876 participants (planned) · Start Feb 18, 2025 · Primary completion Jan 1, 2026
Drug: SHR-1826; SHR-4642 and 7 more · For: Advanced Solid Tumors
Sites: Guangzhou, China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT06754930 · 400 participants (planned) · Start Feb 18, 2025 · Primary completion Dec 2027
Drug: SHR-1826; SHR-1316 and 5 more · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Shanghai, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06915142 · 300 participants (planned) · Start Apr 28, 2025 · Primary completion Dec 2026
Drug: HRS-7058 + SHR-1316; HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy and 11 more · For: Advanced Malignant Tumour
Sites: Beijing, China; Tianjin, China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07059221 · 210 participants (planned) · Start Jul 11, 2025 · Primary completion Mar 2027
Drug: SHR-A2102; Adebrelimab and 3 more · For: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sites: Chongqing, China; Chengdu, China
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT05836948 · 174 participants (planned) · Start May 18, 2023 · Primary completion May 1, 2026
Drug: SHR-9839 · For: Advanced Solid Tumor
Sites: Hangzhou, China
- A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsPivotal-lookingRecruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT06474455 · 156 participants (planned) · Start Jul 2, 2024 · Primary completion Jun 2029
Drug: SHR-9839 for Injection; SHR-A1921 for Injection and 7 more · For: Advanced Solid Tumors
Sites: Zhengzhou, China; Hangzhou, China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07751341 · 84 participants (planned) · Start Sep 7, 2026 · Primary completion Dec 2027
Drug: SHR-9839(sc) for Injection; SHR-9839(sc) for Injection、Adebrelimab Injection、Paclitaxel for Injection、Cisplatin Injecion · For: Advanced Esophageal Squamous Cell Carcinoma
Sites: Beijing, China; Zhengzhou, China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07229638 · 70 participants (planned) · Start Feb 27, 2026 · Primary completion Apr 2027
Drug: SHR-9839(sc) For Injection · For: Solid Tumor
Sites: Nanjing, China; Shanghai, China
- A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D MutationActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06385678 · 47 participants · Start Jul 5, 2024 · Primary completion Dec 2025
Drug: HRS-4642; Adebrelimab and 3 more · For: Advanced KRAS G12D Mutant Solid Tumors
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.